Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7403238 | PMC |
| http://dx.doi.org/10.1007/s11606-020-05840-z | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Clinicopathological significance of androgen receptor expression and tumor infiltrating lymphocytes in triple-negative breast cancer: a retrospective cohort study.
Breast Cancer
December 2024
Department of Pathology, St. Luke's International Hospital, 9-1, Akashi-cho, Chuo-ku, Tokyo, 1048560, Japan.
Background: Triple-negative breast cancer (TNBC) is a serious disease with limited treatment options. We explored the significance of androgen receptor (AR) expression and tumor-infiltrating lymphocytes (TILs) in predicting neoadjuvant chemotherapy (NAC) resistance in TNBC, hypothesizing that AR/TIL classification using pretreatment biopsies can identify NAC-resistant subgroups and improve the understanding of apocrine differentiation.
Methods: This retrospective study included 156 consecutive patients with TNBC treated with NAC.
Identifying subgroups of ypN1 breast cancer patients who may exempt from axillary lymph node dissection after neoadjuvant chemotherapy: insights from a large cohort study.
Breast Cancer
December 2024
The Comprehensive Breast Care Center, The Second Affiliated Hospital of Xi'an Jiaotong University, Xi'an, 710061, China.
Background: In patients with breast cancer staged ypN1 after neoadjuvant chemotherapy (NAC), there is limited evidence-based guidance regarding exemption from axillary lymph node dissection (ALND).
Methods: This study analyzed ypN1 breast cancer patients post-NAC from the Surveillance, Epidemiology, and End Results databases. Patients were categorized into the breast-conserving surgery (BCS) group and the total mastectomy (TM) group, and further divided by the number of positive lymph nodes (LNs).
Clinicopathological characteristics and long-term prognosis of triple-negative breast cancer patients with HER2-Low expression: a retrospective propensity score-matched cohort study.
J Cancer Res Clin Oncol
December 2024
Department of Breast Surgery, Xiangdong Hospital Affiliated to Hunan Normal University, Liling, 412200, Hunan, China.
Purpose: The objective of the current research was to assess the clinicopathological characteristics and long-term prognosis of triple-negative breast cancer (TNBC) patients with human epidermal growth factor receptor 2 (HER2)-low status following breast surgery.
Methods: A total of 202 TNBC patients treated at Qingdao Central Hospital from January 2010 to December 2019 were included, comprising 71 HER2-low and 131 HER2-zero patients. Propensity score matching (PSM) was applied to minimize differences between the cohorts.
Race as a prognostic factor of breast mucinous carcinoma.
J Cancer Res Clin Oncol
December 2024
Department of Breast Surgery, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, 100021, China.
Purpose: The rarity of breast mucinous carcinoma (BMC) makes it challenging to study the prognosis of this disease across diverse racial populations. This study aimed to leverage epidemiological data on immigrant populations to elucidate the prognostic differences in BMC patients from various racial/ethnic backgrounds. The goal was to help formulate more personalized clinical practice guidelines for the management of this rare malignancy.
View Article and Find Full Text PDFPatient-reported outcome based symptom management is a better option for early postoperative recovery after breast cancer surgery: a parallel controlled randomized clinical trial.
Int J Surg
December 2024
Department of Oncology, The Second Affiliated Hospital of Xi'an Jiaotong University, Xi'an, China.
Background: We aimed to assess the efficacy and feasibility of applying patient-reported outcome (PRO) based symptom management in the early postoperative period after breast cancer surgery.
Materials And Method: Before surgery, patients diagnosed with breast cancer who met the inclusion criteria were randomly assigned in a 1:1 ratio to receive either postoperative PRO-based symptom management or usual care. All patients completed the MD Anderson Symptom Inventory-Chinese version (MDASI-C) via the electronic PRO system preoperatively, on a daily basis postoperatively, and twice weekly after discharge, for a duration up to 2 weeks.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!